Key Details:ย ย
– Drug: Vizzโข (aceclidine ophthalmic solution 1.44%)ย ย
– Indication: Treatment of presbyopia in adults.ย ย
– Availability: Expected Q4 2024 (samples in October).ย ย
Mechanism of Actionย ย
Vizz is a once-daily eye drop that:ย ย
1. Contracts the iris sphincter muscle to create a pinhole effect.ย ย
2. Extends depth of focus to improve near vision.ย ย
3. Avoids myopic shift (unlike some corrective lenses).ย ย
Clinical Validation: Phase 3 CLARITY Trialsย ย
| Trial | Participants | Duration | Key Outcomes |ย ย
| CLARITY 1 | 466 adults | 42 days |
โ Met all primary/secondary endpoints<br>โ Near vision improvement within 30 mins<br>โ Effects lasted โค10 hours |ย ย
| CLARITY 2 | 466 adults | 42 days |
โ Identical efficacy to CLARITY 1 |ย ย
| CLARITY 3 | 217 adults | 6 months |
โ Strong long-term safety profile<br>โ No serious treatment-related adverse events |ย ย
Commercial & Patient Impactย ย
– Patient Benefits:ย ย
ย – Reduces dependency on reading glasses.ย ย
ย – Provides “visual freedom” for active lifestyles (โค10 hours).ย ย
– Target Users:ย ย
ย – Contact lens wearers seeking glasses-free near vision.ย ย
ย – Post-refractive surgery patients.ย ย
ย – Active individuals prioritizing discreet correction.ย ย
– Professional Value:ย ย
ย – Offers eye care providers a complementary treatment option to existing solutions.ย ย
Executive Insightย ย
> Eef Schimmelpennink (CEO, Lenz Therapeutics):ย ย
> “Vizz delivers a convenient, transformative solution that lets presbyopes stay in the moment. It addresses unmet needs across diverse patient segments seeking independence from readers.”ย ย
Key Takeawaysย ย
1. FDA approval grounded in robust Phase 3 data (safety + efficacy).ย ย
2. Rapid action: Near vision improvement in 30 minutes.ย ย
3. Sustained effect: Up to 10 hours per dose.ย ย
4. Expanded presbyopia management: Non-invasive alternative to glasses/surgery.